



## **Andrina Sennhauser**

study nurse

Medizinische Onkologie und Hämatologie · Dept. I

### **Contact**

Andrina Sennhauser  
Rorschacherstrasse 95  
9007 St. Gallen

T +41 71 494 3426  
Andrina.Sennhauser@kssg.ch

### **Units**

Medizinische Onkologie und Hämatologie

### **Profile Function**

study nurse

## Publications (0)

No results found.

## Projects (7)

**A first-in-human, open-label, multicenter Phase I/II study to evaluate the safety and anti-tumor activity of ANV600 as single agent and in combination with pembrolizumab in participants with advanced solid tumors (EXPAND-1)**

*Clinical Studies - Jun 13, 2024 - Dec 31, 2028*

*Ongoing*

**A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphoma (EPCORE™ FL-1)**

*Clinical Studies - Dec 7, 2022 - Dec 31, 2029*

*Ongoing*

**A Phase III, randomised, Open-Label, multicenter study evaluating the efficacy and safety of adjuvant GDC-9545 compared with physician's choice of adjuvant endocrine Monotherapy in patients with Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer**

*Clinical Studies - Mar 1, 2022 - Jul 26, 2030*

*Ongoing*

**A Phase II, Open-Label, Multicenter Study Evaluating The Safety And Efficacy Of Neoadjuvant And Adjuvant Tiragolumab Plus Atezolizumab, With Or Without Platinum-Based Chemotherapy, In Patients With Previously Untreated Locally Advanced Resectable Stage II, IIa, Or Select IIIb Non-Small Cell Lung Cancer**

*Clinical Studies - Feb 12, 2021 - Dec 31, 2026*

*Ongoing*

**Vacuum assisted biopsy Immediately before Surgery as an Intra- or pre-Operative surrogate for patient response to Neoadjuvant chemotherapy for breast cancer (VISION I) A multicenter prospective feasibility trial**

*Clinical Studies - Aug 11, 2020 - Dec 31, 2024*

*Ongoing*

**Tailored AXILLary Surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS)**

*Clinical Studies - Jul 30, 2018 - Dec 12, 2030*

*Ongoing*

**A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (KEYVIBE-010)**

*Clinical Studies - Mar 26, 23 - Dec 21, 2030*

*Ongoing*